

Scientific presentations will review state of the art understanding of the brain regions and neural networks critical for memory and the sustenance of independent function from mid-life to old age. Clinically-oriented presentations will update the audience on evaluation and treatment of mild cognitive impairment, both amnesic and non-amnesic forms. This timely conference will provide a unique opportunity for scientists and clinicians, particularly, to focus on a major global health concern.

WHO SHOULD ATTEND

The target audience includes researchers, clinicians, health professionals, fellows, residents and students in the areas of cognitive and affective neuroscience, neuropsychology and psychology who wish to learn current thinking and recent advances in studies of mild cognitive impairment.

EDUCATIONAL CREDITS

Information for physicians and psychologists will be available on the conference website.

DECLARATION OF POTENTIAL CONFLICT OF INTEREST

Speakers will be requested to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of this program.

CANCELLATION POLICY

Refunds will only be made on registration cancellations received prior to February 29, 2012.

All refunds will be subject to an administrative charge of \$75 (\$50 for student registrations).

BAYCREST
3560 BATHURST STREET
TORONTO, ONTARIO
CANADA M6A 2E1

T 416 785 2500
F 416 785 2862
E COMMUNICATIONS@ROTMAN-BAYCREST.ON.CA

RESEARCH.BAYCREST.ORG

Baycrest

MARCH 26-28, 2012

PROUDLY PRESENTS

MILD COGNITIVE IMPAIRMENT*

IMAGINE
THE NEXT GENERATION
OF DISCOVERY



FINDING A NEW PATH
TO TREATING MCI

THE ANNUAL CONFERENCE ON COGNITIVE NEUROSCIENCE

CO-HOSTED BY THE ROTMAN RESEARCH INSTITUTE AND
THE KUNIN-LUNENFELD APPLIED & EVALUATIVE RESEARCH UNIT



Baycrest is an academic health
sciences centre affiliated
with the University of Toronto

T O R O N T O C A N A D A

Our conference will, over three days, bring together internationally renowned neuroscientists and clinicians to provide an update of the field of mild cognitive impairment.

LEARNING OBJECTIVES

At the end of the conference, participants will:

- Understand current theories and research on the neural mechanisms of mild cognitive impairment.
- Be able to debate some of the controversies in mild cognitive impairment evaluation, prognosis, and management.
- Become familiar with theories behind cognitive rehabilitation or prevention of conversion from mild cognitive impairment to dementia.

FORMAT

- *Conference:* The Conference will consist of three days of formal presentations by leading researchers in the fields of cognitive and affective neuroscience, neuropsychology, neuroimaging, and neuropsychiatric clinical research.
- *Questions:* A 5-minute Q&A period will take place after each presentation.
- *Poster Session:* Posters will be available for viewing during the refreshment and lunch breaks. There will be formal Poster Sessions on Tuesday and Wednesday afternoons.
- *Lunch Breaks:* Please note that registrants are expected to make their own arrangements.

MILD COGNITIVE IMPAIRMENT (MCI), THE ANNUAL COGNITIVE NEUROSCIENCE CONFERENCE

THE FOUR SEASONS HOTEL, 21 AVENUE ROAD, TORONTO, CANADA

AM	DAY 1 (MONDAY, MARCH 26, 2012)	DAY 2 (TUESDAY, MARCH 27, 2012)	DAY 3 (WEDNESDAY, MARCH 28, 2012)	AM								
08	REGISTRATION OPENS & BREAKFAST (8 to 9)	REGISTRATION OPENS & BREAKFAST (8 to 9)	REGISTRATION OPENS & BREAKFAST (8:30 to 9)	08								
09	<p>WELCOMING REMARKS (9 to 9:15) Dr. Anthony R. McIntosh, Baycrest; University of Toronto</p> <p>KEYNOTE – NEW DIRECTIONS IN MCI DIAGNOSIS (9:15 to 10) Dr. Marilyn Albert, Johns Hopkins University School of Medicine</p>	<p>WELCOMING REMARKS (9 to 9:15) Dr. Tiffany Chow, Baycrest; University of Toronto</p> <p>KEYNOTE – EPIDEMIOLOGY OF MCI (9:15 to 10) Dr. David Knopman, Mayo Clinic, Minnesota</p>	<p>WELCOMING REMARKS (9 to 9:15) Dr. Nicole Anderson, Baycrest; University of Toronto</p> <p>KEYNOTE – COGNITIVE NEUROSCIENCE (CN) OF MCI (9:15 to 10) Dr. Howard Chertkow, The Bloomfield Centre for Research in Aging; McGill U</p>	09								
10	<p>NEW DIRECTIONS IN DIAGNOSIS: CSF (10 to 10:30) Dr. Alex Henri-Bhargava, Baycrest; University of Toronto</p>	<p>EPIDEMIOLOGY OF MCI: RISK ASSESSMENT FOR ALZHEIMER'S (10 to 10:30) Dr. Scott Roberts, Boston University School of Medicine</p>	<p>(CN) OF MCI: WORKING MEMORY (10 to 10:30) Dr. Sylvie Belleville, Centre de recherche, IUGM</p>	10								
11	REFRESHMENT BREAK (10:30 to 11)	REFRESHMENT BREAK (10:30 to 11)	REFRESHMENT BREAK (10:30 to 11)	11								
12	<p>NEW DIRECTIONS IN DIAGNOSIS: NEPSY (11:30 to 12) Dr. Angela Troyer, Baycrest; University of Toronto, York University</p> <p>NEW DIRECTIONS IN DIAGNOSIS: IMAGING (11:30 to 12) Dr. Howard Chertkow, The Bloomfield Centre for Research in Aging, Montreal</p>	<p>EPIDEMIOLOGY OF MCI: PROTECTIVE/RISK FACTORS (11 to 11:30) Dr. Jose Luchsinger, Presbyterian Hospital, New York</p> <p>EPIDEMIOLOGY OF MCI: NEUROIMAGING (11:30 to 12) Dr. David Salat, Massachusetts General Hospital</p>	<p>(CN) OF MCI: IMAGING MEMORY NETWORKS (11 to 11:30) Dr. Mary Pat McAndrews, University Health Network; University of Toronto</p> <p>(CN) OF MCI: EPISODIC MEMORY RECOLLECTION (11:30 to 12) Dr. Nicole Anderson, Baycrest; University of Toronto</p>	12								
01	LUNCH BREAK (NOT PROVIDED) (12 to 1:30)	LUNCH BREAK (NOT PROVIDED) (12 to 1:30)	LUNCH BREAK (NOT PROVIDED) (12 to 1:30)	01								
02	<p>MCI INTERVENTIONS (1:30 to 2:45) Repeating breakout interest groups [choose any 2 from the following 3] A) Memory Interventions Program – Dr. Kelly Murphy, Baycrest; U of T, York U B) Exercise Interventions – Dr. Louis Bherer, L'Université du Québec à Montréal; IUGM C) Pharmaceuticals – Dr. Morris Freedman, Baycrest; University of Toronto</p>	<p>POSTER SESSION #1 (MODERATED 1:45 to 2:15)</p>	<p>POSTER SESSION #2 (MODERATED 1:45 to 2:15)</p>	02								
03	REFRESHMENT BREAK (2:45 to 3:15)	<p>OVERVIEW: COGNITIVE RESERVE IN MCI (2:30 to 3) Dr. Yaakov Stern, Sergievsky Centre and the Taub Institute, New York</p> <p>COGNITIVE RESERVE IN MCI: LEISURE ACTIVITIES (3 to 3:30) Dr. Joe Verghese, Albert Einstein College of Medicine, New York.</p>	<p>(CN) OF MCI: FUNCTIONAL IMPAIRMENTS (2:30 to 3) Dr. Patrick J. Brown, Columbia University</p> <p>(CN) OF MCI: MOBILITY AND LIFESPACE (3 to 3:30) Dr. Aron Buchman, Armour Academic Centre, Rush College of Medicine, Illinois</p>	03								
04	<table border="1"> <thead> <tr> <th>CLINICAL EVALUATION FOR MCI ARISING FROM THE NEW DIAGNOSTIC CRITERIA</th> <th>NON-AMNESTIC MCI</th> </tr> </thead> <tbody> <tr> <td>A BEDSIDE AND FORMAL NEUROPSYCHOLOGICAL TESTING Dr. Larry Leach, Baycrest; York U</td> <td>D NEUROIMAGING TO ORDER IN WHAT ORDER Dr. Tiffany Chow, Baycrest; U of T</td> </tr> <tr> <td>B THE WIDE RANGE OF VASCULAR COGNITIVE IMPAIRMENT Dr. Sandra Black, Sunnybrook; U of T</td> <td>E DEPRESSION AND COGNITIVE CHANGES Dr. Nasreen Khatri, Baycrest</td> </tr> <tr> <td>C GENETICS AND AMYLOID/TAU BIOMARKERS Dr. Alex Henri-Bhargava, Baycrest; U of T</td> <td>F PARKINSON'S DISEASE AND COGNITIVE CHANGES Dr. Mario Masellis, Sunnybrook; U of T</td> </tr> </tbody> </table>	CLINICAL EVALUATION FOR MCI ARISING FROM THE NEW DIAGNOSTIC CRITERIA	NON-AMNESTIC MCI	A BEDSIDE AND FORMAL NEUROPSYCHOLOGICAL TESTING Dr. Larry Leach, Baycrest; York U	D NEUROIMAGING TO ORDER IN WHAT ORDER Dr. Tiffany Chow, Baycrest; U of T	B THE WIDE RANGE OF VASCULAR COGNITIVE IMPAIRMENT Dr. Sandra Black, Sunnybrook; U of T	E DEPRESSION AND COGNITIVE CHANGES Dr. Nasreen Khatri, Baycrest	C GENETICS AND AMYLOID/TAU BIOMARKERS Dr. Alex Henri-Bhargava, Baycrest; U of T	F PARKINSON'S DISEASE AND COGNITIVE CHANGES Dr. Mario Masellis, Sunnybrook; U of T	REFRESHMENT BREAK (3:30 to 4)	<p>CLOSING REMARKS (3:30 to 4)</p> <p>PLEASE NOTE, EACH SPEAKER TO RESERVE 5 MINUTES FOR Q&A.</p> <p>(CN) = COGNITIVE NEUROSCIENCE</p>	04
CLINICAL EVALUATION FOR MCI ARISING FROM THE NEW DIAGNOSTIC CRITERIA	NON-AMNESTIC MCI											
A BEDSIDE AND FORMAL NEUROPSYCHOLOGICAL TESTING Dr. Larry Leach, Baycrest; York U	D NEUROIMAGING TO ORDER IN WHAT ORDER Dr. Tiffany Chow, Baycrest; U of T											
B THE WIDE RANGE OF VASCULAR COGNITIVE IMPAIRMENT Dr. Sandra Black, Sunnybrook; U of T	E DEPRESSION AND COGNITIVE CHANGES Dr. Nasreen Khatri, Baycrest											
C GENETICS AND AMYLOID/TAU BIOMARKERS Dr. Alex Henri-Bhargava, Baycrest; U of T	F PARKINSON'S DISEASE AND COGNITIVE CHANGES Dr. Mario Masellis, Sunnybrook; U of T											
05	<p>DEBATE #1: TO SCAN FOR AMYLOID OR NOT? (5 to 5:30) Dr. Dave Knopman vs. Dr. Howard Chertkow</p> <p>WELCOME RECEPTION (5:30 TO 6:30)</p>	<p>DEBATE #2: IS THERE A PRE-MCI COGNITIVE SIGNATURE OF AD? (4:30 to 5) Dr. David Knopman versus Dr. Marilyn Albert</p> <p>CALL FOR POSTERS (SUBMISSIONS DUE BY JAN 13, 2012)</p> <p>Posters on research focused on MCI are invited. Submissions must be made on the prescribed forms and must be prepared in exact accordance with instructions.</p> <p>TO LEARN MORE, PLEASE CONTACT: Zipporah Nussbaum Baycrest Research Division E posters@rotman-baycrest.on.ca P (416) 785-2500 ext. 2904</p> <p>All submissions will undergo peer review. Reviewer decisions will be announced by January 27, 2012</p>	<p>PRE-CONFERENCE WORKSHOPS (MARCH 25, 2012)</p> <p>GOAL MANAGEMENT TRAINING (GMT) DETAILS AT RESEARCH.BAYCREST.ORG/GMT</p> <p>THE MEMORY & AGING PROGRAM DETAILS AT RESEARCH.BAYCREST.ORG/MEMORY-AGING</p>	PM								

REGISTRATION

To register on-line please visit:
research.baycrest.org/conference

To register by mail, please use the enclosed registration form.

For additional information, you can contact Paula Ferreira at pferreira@baycrest.org or call 416-785-2500 ext. 2363.

Space is limited, so register early!

VENUE & ACCOMMODATIONS

Registrants who wish to stay at The Four Seasons Hotel will be offered a special room rate:

\$215 ^{CDN} +TAX	SINGLE OR DOUBLE
------------------------------	--------------------------------------

Reservations *must* be made directly with the hotel *before* February 24, 2012. When booking please use the group/ promotional code:



To learn more about the Four Seasons Hotel, please visit fourseasons.com/toronto or call toll-free 1-800-819-5053 (USA & CAN only).

Please see the website for international contact information.